ResearcherLanzhou University Second HospitalActive in the last 2 years
Jubao Niu
Matched on OpenAlex author ID A5101259847. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper
Papers 4
- Neuroimmune crosstalk in pancreatic ductal adenocarcinoma: integrating neuroscience and immuno-oncology. Co-author DOI 10.1016/j.intimp.2026.117371↗
- Reprogramming of glucose metabolism in pancreatic cancer: mechanisms, implications, and therapeutic perspectives. Co-author DOI 10.3389/fimmu.2025.1586959↗
- Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma:… Co-author DOI 10.3389/fimmu.2025.1654425↗
- Research trends on immunotherapy for pancreatic cancer: A bibliometric analysis. Co-author DOI 10.1080/21645515.2023.2269794↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yan Zhang · 2 shared papers, 2025 · strength 0.53
- Paper Reprogramming of glucose metabolism in pancreatic cancer: mechanisms, implications, and therapeutic perspectives. DOI 10.3389/fimmu.2025.1586959↗
- Paper Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or meta… DOI 10.3389/fimmu.2025.1654425↗
- Hui Zhang · 1 shared paper, 2026 · strength 0.32
- Jialong Chen · 1 shared paper, 2026 · strength 0.32
- Zeyang Fan · 1 shared paper, 2025 · strength 0.30
- Xin Li · 1 shared paper, 2025 · strength 0.30
- Hui Zhang · 1 shared paper, 2025 · strength 0.30
- Kongyuan Wei · 1 shared paper, 2025 · strength 0.23
- Hui Zhang · 1 shared paper, 2025 · strength 0.23
- Xin Li · 1 shared paper, 2025 · strength 0.23
- Wenke Qin · 1 shared paper, 2025 · strength 0.23
- Wence Zhou · 1 shared paper, 2023 · strength 0.22
- Hui Zhang · 1 shared paper, 2023 · strength 0.22
- Wenkai Jiang · 1 shared paper, 2023 · strength 0.22
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.